| CAS NO: | 634911-47-0 |
| 包装 | 价格(元) |
| 250mg | 电议 |
| 500mg | 电议 |
| Cas No. | 634911-47-0 |
| Canonical SMILES | CNC1=CC=C(/C=C/C2=NC3=CC=C(OCCF)C=C3O2)C=C1 |
| 分子式 | C18H17FN2O2 |
| 分子量 | 312.34 |
| 溶解度 | Soluble in DMSO |
| 储存条件 | Store at -20°C,unstable in solution, ready to use. |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | BF-168, a candidate probe for PET, is found to specifically recognize both neuritic and diffuse plaques, with a Ki of 6.4 nM for Aβ1-42. BF-168, a styrylbenzoxazole derivative, is a potent agent that selectively recognizes SPs and NFTs in AD brain. BF-168 is a candidate probe for PET and is found to specifically recognize both neuritic and diffuse plaques, with a Ki of 6.4 nM for Aβ1-42[1]. Intravenous injection of BF-168 in PS1/APP and APP23 transgenic mice result in specific in vivo labeling to both compact and diffuse amyloid deposits in the brain. In addition, 18F-radiolabeled BF-168 demonstrates abundant initial brain uptake (3.9% injected dose/gm at 2 min after injection) and fast clearance (t1/2=24.7 min) after intravenous administration in normal mice. Furthermore, autoradiograms of brain sections from APP23 transgenic mice at 180 min after intravenous injection of [18F]BF-168 shows selective labeling of brain amyloid deposits with little nonspecific binding[1]. [1]. Okamura N, et al. Styrylbenzoxazole derivatives for in vivo imaging of amyloid plaques in the brain. J Neurosci. 2004 Mar 10;24(10):2535-41. |
m.cnreagent.com